Payers Beware: J&J, Merck Try To Facilitate Use Of Their HCV Agents With Gilead’s Sovaldi
This article was originally published in The Pink Sheet Daily
Executive Summary
Janssen and Merck are pursuing clinical development strategies that may make reimbursement less challenging for co-administration of their HCV drugs with Sovaldi. Janssen has filed an sNDA for co-administration of its Olysio with Sovaldi in fibrotic patients, while Merck is beginning a combination trial looking at a four-week duration of therapy.